Although cancer is known to be characterized by several unifying biological hallmarks, systems biology has had limited success in identifying molecular signatures present in in all types of cancer. The current availability of rich data sets from many different cancer types provides an opportunity for thorough computational data mining in search of such common patterns. Here we report the identification of 18 "pan-cancer" molecular signatures resulting from analysis of data sets containing values from mRNA expression, microRNA expression, DNA methylation, and protein activity, from twelve different cancer types. The membership of many of these signatures points to particular biological mechanisms related to cancer progression, suggesting that they represent important attributes of cancer in need of being elucidated for potential applications in diagnostic, prognostic and therapeutic products applicable to multiple cancer types.
Although cancer is known to be characterized by several unifying biological hallmarks, systems biology has had limited success in identifying molecular signatures present in in all types of cancer. The current availability of rich data sets from many different cancer types provides an opportunity for thorough computational data mining in search of such common patterns. Here we report the identification of 18 "pan-cancer" molecular signatures resulting from analysis of data sets containing values from mRNA expression, microRNA expression, DNA methylation, and protein activity, from twelve different cancer types. The membership of many of these signatures points to particular biological mechanisms related to cancer progression, suggesting that they represent important attributes of cancer in need of being elucidated for potential applications in diagnostic, prognostic and therapeutic products applicable to multiple cancer types.
Cancer is known to be not just one disease, but many diseases, as evidenced by the diversity of its pathological manifestations. On the other hand, it has been appreciated that there exist some unifying capabilities, or "hallmarks," characterizing all cancers, as proposed in two seminal papers 1, 2 . It is reasonable to hypothesize that such common biological traits would be represented by particular patterns detectable in data sets derived from cancer samples. However, systems biology has had limited success in finding such common patterns until recently. The current availability of integrated biomolecular data sets from twelve cancer types ("pancan12") in The Cancer Genome Atlas (TCGA) provides an opportunity for thorough data mining, so that such common patterns can be computationally discovered and defined with high accuracy.
Our data mining approach 3 uses an iterative algorithm to identify patterns that manifest themselves as distinct molecular signatures, called attractor metagenes, several of which were found in nearly identical form following separate analysis of data sets from multiple different cancer types. The algorithm is designed to converge to the core of gene coexpression patterns, without being influenced in any way by other constraints, such as classification of samples into subtypes. These signatures are manifested by the coordinate observed presence of many features (such as expression of genes or methylation of genomic sites), to varying degrees, in multiple cancer types. The three main molecular signatures that we previously found 3 using data sets from three cancer types are associated with mitotic chromosomal instability (CIN), mesenchymal transition (MES) and a lymphocyte-specific immune recruitment (LYM). We hypothesized that these molecular signatures represent important biomolecular events of cancer, and therefore that they would be associated with phenotypes in multiple cancer types. Consistent with this hypothesis, a computational model using attractor metagenes as features recently won the Sage Bionetworks/DREAM Breast Cancer Prognosis Challenge 4, 5 .
Here we report our results of discovering "Pan-Cancer" molecular signatures applying the same computational methodology (Methods) on the TCGA pancan12 data sets. Based on parameter choices that would guarantee that such signatures are clearly present in the majority of the data sets and would involve a significant number of mutually associated genes.
RESULTS

Listing of 18 Pan-Cancer signatures
We identified 15 attractor molecular signatures, seven of which were present in mRNA expression data sets, three in DNA methylation data sets, three in microRNA expression data sets, and two in protein activity data sets. We found several additional genomically co-localized molecular signatures, mainly representing amplicons, and we report on three of them, for a total of 18 attractor signatures.
The signatures identified separately in individual cancer types available under Synapse ID syn1899444. The consensus ranked lists for each of these signatures are presented in Table S1 , as well as under Synapse ID syn1899445. We also identified genomically co-localized molecular signatures, presented under synapse ID syn1899446. The first two such signatures (MHC Class II and GIMAP gene cluster) are strongly associated with the LYM metagene. The third signature contains the Pan-Cancer chr8q24.3 amplicon, which we had previously identified 3 as the strongest amplicon attractor metagene.
We confirmed that the three main attractor metagenes (CIN, MES, LYM) that we previously identified 3 are the most prominent ones (using a measure of signature strength defined in Methods) among all 18 signatures. In addition, we identified several new attractor metagenes resulting from this new thorough analysis, one of which (END) contains endothelial markers and is associated with angiogenesis.
A striking visualization consistent with the co-expression of these Pan-Cancer molecular signatures can be made in the form of scatter plots. For example, Fig. 1 shows such color-coded scatter plots for the four main attractor metagenes CIN, MES, LYM, and END, in all twelve cancer types using the three top-ranked genes for each of these four signatures. In each scatter plot, samples represented by dots at the lower left (blue) side have low levels of the signature, while samples represented by dots at the upper right (red) side have high levels of the signature. Fig. S1 shows the corresponding scatter plots for all 18 identified attractor molecular signatures demonstrating such coexpression in all cases. Scrutinizing each of these molecular signatures provides opportunities for discovery in cancer biology. Table 1 provides a summary of the 18 signatures, including brief comments and a listing of their top-ranked members. In the following , we briefly describe each of them. The horizontal and vertical axes measure the expression values of two of the three genes, while the value of the third gene is color-coded. The observed linear change from lower left (blue) to upper right (red) demonstrates the coexpression of these three genes. Shown are scatter plots for the top-ranked three genes of (a) the CIN metagene, (b) the MES metagene, (c) the LYM metagene and (d) the END metagene. Table1 -continued from previous page   Name  Top members  Comments   END  CDH5, ROBO4, CXorf36, CD34, CLEC14A, ARHGEF15,  CD93, LDB2, ELTD1, MYCT1   endothelial markers   "AHSA2"  AHSA2, LOC91316, PILRB, ZNF767, TTLL3, CCNL2,  PABPC1L, LENG8, CHKB CPT1B, SEC31B   IFIT  IFIT3, MX1, OAS2, RSAD2, CMPK2, IFIT1, IFI44L, IFI44 These three signatures are related to tumor infiltration by lymphocytes. We list them together because they are strongly interrelated (Fig. 2) even though each of the three was independently derived using an unsupervised computational method. The presence of LYM is accompanied by the presence of M+ and the absence of M-in all solid cancer types, suggesting that the three signatures reflect the same biomolecular event, which appears to be the infiltration of immune cells in tumor tissue. Indeed, there is remarkable similarity (Fig. 3) between the LYM signature and the "immune score" of the ESTIMATE tumor purity computational tool (http://ibl.mdanderson.org/estimate). The values of the M+ methylation signature are also remarkably similar to those of the methylation-based "leukocyte percentage" estimation 6 (available under Synapse ID syn1809222).
We had previously found 7 all three LYM, M+ and M-signatures from their association with the expression of miR-142. We have now confirmed this association with miR-142 in the pancan12 data sets, and we found that miR-150 and miR-155 are also strongly associated with the LYM signature. We had also previously independently identified the LYM signature as an attractor metagene 3 , and used it in the winning model of the Sage Bionetworks Breast Cancer Prognosis Challenge 4 . Specifically the LYM signature is strongly associated with improved prognosis in ER-negative breast cancers, and this fact also provides an explanation for the relatively better prognosis in medullary, compared with other types of high-grade breast cancers.
The interrelationship of the LYM, M+ and M-signatures, as shown in Fig. 2 , appears to be a consequence of the presence of different subclasses of cells (as opposed to being a methylation switch inside the same cell), consistent with their assumed role of measuring the extent of lymphocyte infiltration in the tumor. In other words, the M+ methylation sites, normally In all three cases, the metagene is defined by the average of the top ranked genes as described in Table S1 . unmethylated, are largely methylated in the infiltrating leukocytes; and the M-methylation sites, normally methylated, are largely unmethylated in the infiltrating leukocytes. Consistently, many of the genes methylated by the M-signature are identical to those of LYM (six among the 27 genes of the M-signature (BIN2, TNFAIP8L2, ACAP1, NCKAP1L, FAM78A, PTPN7) listed in Table S1 are also among the 168 genes listed in the LYM attractor metagene (P < 9.21 × 10
based on Fishers exact test). The observed significant overlap in the gene sets and the negative association between gene expression in LYM and DNA methylation in M-are consistent with the notion that the absence of DNA methylation is permissive for gene expression, suggesting that the expression of the LYM signature in the infiltrating lymphocytes may be facilitated in part by the hypomethylation of the M-signature.
The sharp definition of the LYM signature (being a Pan-Cancer attractor signature pointing to few genes at the core of coexpression) provides strong hints about the precise nature of this leukocyte infiltration. Specifically, the membership of the top-ranked genes (SASH3, CD53, NCKAP1L, LCP2, IL10RA, PTPRC, EVI2B, BIN2, WAS, HAVCR2, . . . ) point to a specific type of lymphocytes. We have speculated 3 that these infiltrating lymphocytes are T cells having undergone a particular type of co-stimulation providing hypotheses for related adoptive transfer therapy.
Two proteins strongly associated with the LYM signature are two tyrosine kinases: Lck (lymphocyte-specific protein tyrosine kinase) and Syk (spleen tyrosine kinase).
CIN (mitotic chromosomal instability) mRNA signature
This signature is related to mitotic chromosomal instability. It is similar to numerous known "proliferation" signatures, but its sharp definition as an attractor metagene specifically points to the kinetochore-microtubule interface and associated kinesins. Comparison with similar mitotic signatures in normal cells may help pinpoint driver genes for malignant chromosomal instability. The signature is strongly associated with tumor grade as well as poor prognosis in many, if not all, cancer types.
Two proteins strongly associated with the CIN signature are Cyclin B1 and CDK1. Consistently, it is known that the cyclin B1-Cdk1 complex of cyclin-dependent kinase 1 is involved in the early events of mitosis, and that nuclear cyclin B1 protein may induce chromosomal instability and enhance the aggressiveness of the carcinoma cells 8 .
MES (mesenchymal transition) mRNA signature
This signature is related to mesenchymal transition and invasiveness of cancer cells. It is similar to numerous "stromal" or "mesenchymal" signatures; however there is evidence 9 that many among the genes of the signature are largely produced by transdifferentiated cancer cells. We hypothesize that such cells, known to assume the duties of cancer-associated fibroblasts in some tumors 2 , may have become indistinguishable, even using laser capture microdissection, from stromal fibroblasts. We had originally identified the MES signature from its association with tumor stage 10 ; specifically the signature appears only after a particular cancer type-specific tumor stage threshold has been reached.
The values of the MES signature are remarkably similar to the "stromal score" of the ESTIMATE tumor purity computational tool (http://ibl.mdanderson.org/estimate) measuring fibroblast infiltration. Based on our previous reasoning, however, we believe that this interpretation may not be fully accurate, and that it will be important to find out to what extent some of the cells expressing some of these mesenchymal markers may actually be transdifferentiated cancer cells, and whether the estimated tumor purity may be affected by other types of normal cells instead of stromal fibroblasts.
The co-regulated microRNAs most strongly associated with the MES signature are miR-199a, miR-199b, and miR-214. The DLK1-DIO3 RNA cluster attractor signature, described later, is also strongly associated with MES.
The protein most strongly associated with the MES signature is Fibronectin.
END (endothelial marker) mRNA signature
This is a novel angiogenesis-associated attractor signature. Nearly all the top-ranked genes ( Table  1 ) are endothelial markers. The top gene, CDH5, codes for VE-cadherin, which is known to be involved in a pathway suppressing angiogenic sprouting 11 . The second gene, ROBO4, is known to inhibit VEGF-induced pathologic angiogenesis and endothelial hyperpermeability 12 . Consistently, the END attractor metagene appears to be protective and anti-angiogenic, stabilizing the vascular network. For example, 22 out of the 27 genes of the END attractor are among the 265 genes included in File S2 of a recent study 13 of renal cell carcinoma (P < 8.4 × 10 −38 based on Fishers exact test) as most associated with patients survival. These good-prognosis genes were intermixed in the same file with many poor-prognosis genes of the CIN attractor, suggesting that the CIN and END attractor metagenes are two of the most prognostic features in renal cell carcinoma.
Interestingly, the MES and END attractor metagenes are positively associated with each other (Fig. 4) , in the sense that overexpression of the END signature tends to imply overexpression of the MES signature and vice-versa. This is consistent with mutual exclusivity between angiogenesis and invasiveness and with related findings 14 that VEGF inhibits tumor cell invasion and mesenchymal transition, while antiangiogenic therapy is associated with increased invasiveness 15 . It may also explain the paradoxical protective nature of signatures related to the MES attractor metagene in invasive breast cancers 16 . This association suggests that the invasive MES signature and the antiangiogenic END signature tend to be present simultaneously.
"AHSA2" mRNA signature
We do not yet know what this signature represents. We observed that several noncoding RNAs (e.g. NCRNA00105, NCRNA00201) are in relatively high-ranked positions among its members.
IFIT (interferon-induced) mRNA signature
The members of this signature are interferon-induced. For example, we observed large enrichment of the genes of the signature among those upregulated by IFN-α in the side population (SP) of ovarian cancer cells 17 from the list provided in Supplementary Table S4 of that paper, in which the authors concluded that tumors bearing large SP numbers could be particularly sensitive to IFN-α treatment.
"WDR38" mRNA signature
We do not know what this signature represents, except that we had found one of its key members, gene ZMYND10, to be protective and associated with estrogen receptor expression in breast cancer.
MHC Class II genomically co-localized mRNA signature
We found this signature using the genomically co-localized version of the algorithm. It is very highly correlated with LYM.
GIMAP genomically co-localized mRNA signature As above, we found this signature using the genomically co-localized version of the algorithm. It is also very highly correlated with LYM.
Chr8q24.3 amplicon mRNA signature
This is the strongest pan-cancer amplicon signature. It was previously found predictive of early relapse in ER-positive breast cancers 18 .
"RMND1" methylation signature The DLK1-DIO3 cluster of noncoding RNAs. Shown is a screen capture from the UCSC Genome Browser (http://genome.ucsc.edu). The cluster of imprinted genes delineated by the DLK1 and DIO3 genes (outside the shown region) is located on chromosome 14. We found that the corresponding pancancer attractor signature does not contain any paternally inherited protein-coding genes. It does contain the numerous noncoding RNA genes expressed from the maternally inherited homolog, including the MEG3 long noncoding RNA gene.
DLK1-DIO3 RNA cluster signature
This is the strongest pan-cancer multi-microRNA coexpression signature. It consists of numerous noncoding RNAs within the DLK1-DIO3 imprinted genomic region of chr14q32. Fig. 5 shows a screen capture of the genomic region from the UCSC Genome Browser (http://genome.ucsc.edu/). We confirmed that the coexpression signature also includes the MEG3 long noncoding RNA located at the upstream end of the region. It may also include numerous small nuclear RNAs at the central region, but there were no associated probe sets to confirm the coexpression. We found that this ncRNA signature is associated with the MES (mesenchymal transition) mRNA signature. For example, the ranked list of mRNAs most associated with the DLK1-DIO3 ncRNA signature starts from POSTN, PCOLCE, COL5A2, COL1A2, GLT8D2, COL5A1, SFRP2, and FAP.
Expression of the imprinted DLK1-DIO3 ncRNA cluster is believed to be vital for the development potential of embryonic stem cells 19 , consistent with the hypothesis 20 that mesenchymal transition in cancer reactivates embryonic developmental programs and makes cancer cells invasive and stem-like. The DLK1-DIO3 ncRNA signature was also found to define a stem-like subtype of hepatocellular carcinoma associated with poor survival 21 . The details of the regulation mechanism for this ncRNA cluster coexpression in the DLK1-DIO3 region are unclear.
"miR-509/miR-514/miR-508" microRNA signature These three microRNAs are co-localized at chrXq27.3. We do not know what this signature signifies.
"miR-144/miR-451/miR-486" microRNA signature This is a three-microRNA signature related to erythropoiesis. The first two genes are located in the bicistronic microRNA locus miR-144/451, highly expressed during erythrocyte development 22 . The mRNAs most associated to this microRNA signature are hemoglobin-related: HBB, HBA1, HBA2 and ALAS2. The protein most associated with this signature is HER3. These three microRNAs were identified as promising biomarkers for detection of esophageal cancer.
c-Met/Snail/PARP cleaved/Caspase-8/ERCC1/Rb protein activity signature This protein coexpression signature appears to combine the contribution of several pathways and we hope that a plausible and useful biological "story" will be developed based on the simultaneous activity of all these six proteins in some cancer samples. We note that each of these proteins [23] [24] [25] [26] [27] [28] has been related in various ways with resistance to chemotherapy or apoptosis.
Akt/Tuberin/STAT5A protein activity signature
We do not know what the coexpression of Akt, Tuberin, STAT5A proteins represents in cancer. It is known, however, that low levels of STAT5A protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes 29 .
DISCUSSION
The Pan-Cancer nature (Fig. S1) of each of the signatures described in this paper suggests that they represent important biomolecular events. A reasonable concern is whether some of these "pan-cancer" signatures may instead reflect fundamental normal "pan-tissue" biological mechanisms. Even if this is true for some of these signatures, this does not exclude the possibility that they are aberrant and play important roles in some cancer samples. Furthermore, this provides the opportunity to compare similar signatures in normal vs. malignant tissues to pinpoint potential cancer-specific genes.
Because of its exhaustive search starting from all potential "seeds" in all data sets from twelve different cancer types, our iterative data mining algorithm is guaranteed to have identified all pan-cancer molecular signatures involving simultaneous presence of a large number of coordinately expressed genes, proteins, or comethylated sites. We hope that these signatures are further scrutinized by the medical research community for the purpose of developing potential diagnostic, predictive, and eventually therapeutic products applicable in multiple cancers.
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METHODS
Data normalization
The data platform for each cancer types and its corresponding Synapse ID is given below. For each RNA sequencing and miRNA sequencing data set, the mRNAs or miRNAs in which more than 50% of the samples have zero counts were removed from the data set. All the zero counts and missing values in the data sets were imputed using the k-nearest neighbors algorithm as implemented in the impute package in Bioconductor. The log2 transformed counts were then normalized using the quantile normalization methods implemented in Bioconductor's limma package. The missing values in the protein and DNA methylation data sets were also imputed using the k-nearest neighbors algorithm in the impute package. We summarized the miRNA expression values by taking the average expression values of the miRNAs with the same gene family names. For bladder and head and neck methylation data sets, for which only the Humanmethylation450 platform were provided, we extracted the 23,380 overlapping probes between the Humanmethylation27 and HumanMethylation450 platforms as new data sets for analysis.
Finding attractors
The iterative algorithm for finding converged attractors was previously described 3 and is available as an R package under Synapse ID syn1123167. We used the same parameters as in our previous work. Specifically, we selected the value of the exponent a to be 5 for mRNA sequencing, and we used the same value for miRNA sequencing and for DNA methylation. For protein data sets due to their smaller dimension, the exponent was set to 2. For genomically co-localized mRNA attractors, the parameters were set as previously defined 3 . The strength of an attractor (to be used for attractor ranking as described below) was defined as the k-th highest mutual information among all genes with the converged attractor. For mRNA and methylation attractors, we set k = 10, and for miRNA and protein attractors, we defined k = 3, because we observed that these attractors tend to consist of a smaller number of mutually associated elements.
Clustering attractors of different cancer types
After obtaining the converged attractors in each data set, we performed a clustering algorithm to identify extremely similar attractors across different cancer types, using the same algorithm as in our previous work 3 . We used the top features mRNAs, miRNAs, proteins, or methylation probes in each attractor as a feature set, then performed hierarchical clustering on the feature sets across the cancer types, using the number of overlapping features as the similarity measure. The number of top features used to represent the attractor was chosen according to the distribution of the features' weights in the attractors. For the mRNA attractors, we used the top 20 features to create such feature sets. For the methylation attractors, we used top 50 features for clustering. For the miRNA and protein attractors, we used the top five features for clustering. We removed a methylation attractor cluster containing sites exclusively on the X or Y chromosome, because we found that their values were gender-based. If an attractor cluster did not contain any gene that found in at least six cancer types, it was removed from consideration.
Creating consensus molecular signatures
To account for the fact that some of the twelve data sets may not contain sufficient heterogeneous samples for showing each Pan-Cancer biomolecular event, the decision of selecting a signature was based on its clear presence in at least half of the cancer types, i.e., six different cancer types. We thus created a consensus molecular signature from each attractor cluster as follows: We first identified, for each cluster, six significant attractors by calculating the sum of the similarity measures (as defined above) between each attractor and all the other attractors, ranking the attractors using this quantity, and selecting the six top-ranked attractors. If an attractor cluster contained less than six attractors, it was removed from consideration. We then calculated the average score for each feature across the six attractors and ranked the features accordingly as the consensus ranking. The ranking of the features is provided in Table S1 .
Data visualization
To create scatter plots for the top three features in the attractor, we median-centered the values of the features on both axes, so the median value for each feature in each data set is zero on the scatter plots. For the color-coded feature, we set the median to be gray, the minimum value to be blue, and the maximum value to be red, and interpolated the colors for intermediate values. For mRNA sequencing and miRNA sequencing data, the outlier values were removed, where the outliers were identified using the boxplot function in R.
Ranking attractor clusters
The strength of an attractor cluster was defined as the average strength of the six selected attractors in the cluster, as identified in the previous section. Figure S1 : Scatter plots of the top three features for each of the 15 molecular signatures, demonstrating strong mutual association in nearly all cases, with very few exceptions, usually in leukemia. Each dot represents a cancer sample. The horizontal and vertical axes measure the values of two of the three features, while the value of the third feature is color-coded from blue to red. 
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